Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2017

Published: Sep, 2017 | Pages: 85 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Histone Deacetylase 3 - Pipeline Review, H2 2017'; Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. 

Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It participates in the regulation of transcription through its binding with the zinc-finger transcription factor YY1. This protein can also down-regulate p53 function and thus modulate cell growth and apoptosis. 

The report 'Histone Deacetylase 3 - Pipeline Review, H2 2017' outlays comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 1, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Dermatology, Gastrointestinal, Genetic Disorders, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Follicular Lymphoma, Non-Small Cell Lung Cancer, Melanoma, Myelodysplastic Syndrome, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mantle Cell Lymphoma, Metastatic Renal Cell Carcinoma, Non-Hodgkin Lymphoma, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Solid Tumor, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenoid Cystic Carcinoma (ACC), Alopecia, Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Bone Disorders, Burkitt Lymphoma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), CNS Lymphoma, Cutaneous T-Cell Lymphoma, Drug Addiction, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Liver Fibrosis, Lung Adenocarcinoma, Lung Cancer, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Neuroblastoma, Neurodegenerative Diseases, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Ductal Adenocarcinoma, Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Post-Traumatic Stress Disorder (PTSD), Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Soft Tissue Sarcoma, T-Cell Leukemia and Thyroid Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Overview 7
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 15
Products under Development by Universities/Institutes 21
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Assessment 23
Assessment by Mechanism of Action 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Companies Involved in Therapeutics Development 28
4SC AG 28
Chipscreen Biosciences Ltd 28
Curis Inc 29
HitGen LTD 30
IRBM Science Park SpA 30
Medivir AB 31
Merck & Co Inc 31
Sigma-Tau SpA 32
Syndax Pharmaceuticals Inc 32
Zhejiang Hisun Pharmaceutical Co Ltd 33
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Drug Profiles 35
4SC-202 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
CUDC-907 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Drug to Inhibit HDAC-3 for Oncology - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
entinostat - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
HG-3001 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
KDAC-0001 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
largazole - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
remetinostat - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
ST-3595 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
tucidinostat - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
vorinostat - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Dormant Products 71
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Product Development Milestones 73
Featured News & Press Releases 73
Jul 11, 2017: Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy 73
May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting 73
May 17, 2017: Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Advanced Melanoma 74
May 16, 2017: Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies 75
Apr 20, 2017: Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting 76
Apr 19, 2017: GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer 76
Apr 11, 2017: New mechanistic insights into 4SC-202's epigenetic mode of action 77
Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma 78
Jan 05, 2017: Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors 79
Nov 08, 2016: Syndax Pharmaceuticals to Present Data On Entinostat at the SITC 31st Annual Scientific Meeting 79
Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 80
Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 80
May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting 81
Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting 82
Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 83
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 84
Disclaimer 85

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Indications, H2 2017 10
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 13
Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 14
Number of Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 16
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 17
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 18
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 19
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 20
Number of Products under Investigation by Universities/Institutes, H2 2017 21
Products under Investigation by Universities/Institutes, H2 2017 22
Number of Products by Stage and Mechanism of Actions, H2 2017 23
Number of Products by Stage and Route of Administration, H2 2017 25
Number of Products by Stage and Molecule Type, H2 2017 27
Pipeline by 4SC AG, H2 2017 28
Pipeline by Chipscreen Biosciences Ltd, H2 2017 29
Pipeline by Curis Inc, H2 2017 30
Pipeline by HitGen LTD, H2 2017 30
Pipeline by IRBM Science Park SpA, H2 2017 31
Pipeline by Medivir AB, H2 2017 31
Pipeline by Merck & Co Inc, H2 2017 32
Pipeline by Sigma-Tau SpA, H2 2017 32
Pipeline by Syndax Pharmaceuticals Inc, H2 2017 33
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017 34
Dormant Products, H2 2017 71
Dormant Products, H2 2017 (Contd..1), H2 2017 72